AllianceBernstein
NAVB

AllianceBernstein’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

AllianceBernstein’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,770
Closed -$33K – 3021
2016
Q1 		$33K Sell
1,770
-525
-23% -$10.1K ﹤0.01% 2888
2015
Q4 		$61K Hold
2,295
– – ﹤0.01% 2880
2015
Q3 		$105K Hold
2,295
– – ﹤0.01% 2877
2015
Q2 		$74K Buy
2,295
+255
+13% +$7.41K ﹤0.01% 2968
2015
Q1 		$65K Sell
2,040
-695
-25% -$23.5K ﹤0.01% 3102
2014
Q4 		$103K Sell
2,735
-680
-20% -$18.7K ﹤0.01% 2984
2014
Q3 		$90K Hold
3,415
– – ﹤0.01% 2989
2014
Q2 		$101K Buy
3,415
+35
+1% +$1.13K ﹤0.01% 2994
2014
Q1 		$125K Sell
3,380
-1,105
-25% -$41.9K ﹤0.01% 2924
2013
Q4 		$186K Sell
4,485
-2,950
-40% -$115K ﹤0.01% 2808
2013
Q3 		$394K Sell
7,435
-577
-7% -$33.6K ﹤0.01% 2594
2013
Q2 		$428K Buy
+8,012
New +$400K ﹤0.01% 2562

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

AllianceBernstein's NAVB Position: Q2 2016 in Review

AllianceBernstein sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 1,770 shares — an estimated $33K sold.

AllianceBernstein first reported a position in NAVB in Q2 2013 and held it in 12 quarters. The position peaked at $428K in Q2 2013. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

  • AllianceBernstein reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • AllianceBernstein sold 1,770 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $33K.
  • AllianceBernstein first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 12 quarters.
  • AllianceBernstein's Navidea Biopharmaceuticals Inc. position peaked at $428K in Q2 2013.
  • 63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on AllianceBernstein's 13F filing for Q2 2016, filed 11 Aug 2016.